# Pediatrix Medical Group account plan

> Pediatrix Medical Group is a US provider of newborn, maternal-fetal and pediatric physician services, with $1.91 billion net revenue in FY2025.

## At a glance

Pediatrix Medical Group (NYSE: MD), based in Sunrise, Florida, provides physician services in newborn, maternal-fetal and other pediatric subspecialty care, mainly in hospital NICUs. At December 31, 2025 it had approximately 2,295 affiliated physicians practising in 37 states, retained by approximately 400 hospitals, plus approximately 2,020 other clinical professionals and approximately 2,260 other employees. FY2025 net revenue was $1.91 billion (down 4.9% after exiting most office-based practices in 2024), with net income of $165.4 million and Adjusted EBITDA of $275.6 million. Texas alone produced about 32% of net revenue, and the five largest states about 64%.

## Business units

- **Neonatal care (NICUs)** (1,350 of approximately 2,295 affiliated physicians): Neonatologists and other pediatric clinicians staff and manage over 360 NICUs in 32 states, generally with 24/7 coverage, for not-for-profit and for-profit hospitals. It includes the newborn nursery program, where volumes declined in 2026, and is supported by the BabySteps clinical documentation system.
- **Maternal-fetal medicine and obstetrics** (over 475 affiliated physicians): Inpatient and office-based care for complicated pregnancies, located mainly in metropolitan areas where Pediatrix also has neonatologists. It is the only office-based business kept after the 2024 portfolio review and led same-unit volume growth in Q3 2026; one MFM practice was acquired in 2026.
- **Pediatric intensive care** (over 230 affiliated physicians): Pediatric intensivists staff and manage PICUs at approximately 60 hospitals, caring for critically ill or injured children and adolescents.
- **Pediatric hospitalists** (220 affiliated physicians): Hospital-based pediatricians provide inpatient pediatric and newborn care in PICUs, well-born nurseries and pediatric emergency rooms at over 50 hospitals.
- **Pediatric surgery** (20 affiliated physicians): Pediatric plastic and craniofacial surgeons and general and thoracic pediatric surgeons covering neonatal and congenital anomalies, trauma, oncology and gastrointestinal surgery.
- **Newborn hearing screening program**: Run since 1994 and believed by the company to be the largest US provider of newborn hearing screening; in 2025 it screened over 793,000 babies at 340 hospitals.

## Strategic priorities

- **Hospital-based and maternal-fetal focus**: After exiting almost all office-based practices other than maternal-fetal medicine and its primary and urgent care line in 2024, management decided to return to a hospital-based and maternal-fetal medicine-focused organization; all practice dispositions are now behind it.
- **Nationwide telehybrid medicine**: Pediatrix is building a teleservices function on top of its physical footprint of over 170 MFMs and over 360 NICUs, extending into retinopathy, neurology, infectious disease and neonatology, and has recruited a leader for it.
- **OB hospitalist expansion**: The company is expanding OB hospitalist services across its relationships with over 400 hospitals and named select opportunities in the field as a growth priority in Q3 2026.
- **Acquisitions in women's and children's care**: With leverage just under 1x and cash of $312 million, management says it can make larger acquisitions, staying in the women's and children's space, possibly with outside JV and capital investors.
- **Clinical data and technology**: Its clinical data warehouse holds information on more than 2.1 million patients and is used to report outcomes to physicians and hospital partners, alongside charge-capture, cloud imaging and AI documentation tools.
- **Share buybacks**: A $250.0 million programme was authorised in August 2025; $228.5 million had been used by September 30, 2026.

## Latest results

In Q3 2026 net revenue rose 1.7% to $501.4 million, mainly from acquisitions net of dispositions, with same-unit revenue up 0.6%. Net income fell to $47.0 million from $71.7 million, as Q3 2025 included a $20.9 million gain on divested businesses, and Adjusted EBITDA was $85.5 million versus $87.3 million. Operating margin slipped to 13.0% from 13.8% as clinical salaries rose faster than revenue. Over nine months net revenue was $1.47 billion (+3.2%) and Adjusted EBITDA $220.1 million versus $209.7 million. The full-year 2026 Adjusted EBITDA outlook was narrowed to $290 million to $300 million; no 2027 outlook was given.

## Investments and deals

- **Practice acquisitions**: 2025 acquisition payments were $23.2 million (one MFM practice plus a multi-practice neonatology, MFM and OB hospitalist deal); in 2026 one maternal-fetal medicine practice was acquired for total consideration of $7.9 million.
- **Stock repurchases**: $147.2 million of stock was repurchased in the first nine months of 2026; about 10 million shares have been bought since August 2025 at an average $23.
- **Revenue cycle management transition**: Pediatrix moved to a hybrid revenue cycle management model away from an outsourced provider; transformational and restructuring expenses were $22.3 million in 2025 and $19.5 million in the first nine months of 2026.

## Challenges and risks

- **Medicaid and payor mix pressure**: Government programs were 24% of FY2025 payor mix, and the One Big Beautiful Bill Act is expected by the CBO to cut federal Medicaid and CHIP spending; ACA premium increases of approximately 15% are proposed for 2027.
- **Declining volumes**: Nine-month 2026 same-unit volume fell 0.9% with declines across all service lines, and a declining US birth rate is a stated risk; management expects 2026 volume flat to slightly down.
- **Rising clinical costs**: Practice salaries and benefits rose 2.8% to $341.5 million in Q3 2026, with clinical salary growth of about 3% to 3.5%.
- **Debt maturity and state concentration**: The credit agreement matures in February 2027, making the $178.1 million Term A Loan current, and about 64% of net revenue comes from five states.
- **Regulation and compliance**: Surprise-billing rules and the IDR process, billing compliance, malpractice exposure, physician recruitment and retention, cybersecurity and AI use are named risks.

## What leadership says

> "we have a very strong balance sheet, and we have the ability to make larger acquisitions." — Mark S. Ordan, Chief Executive Officer, Q3 2026 earnings call, October 29, 2026

> "staying in the women's and children's space is important to us." — Mark S. Ordan, Chief Executive Officer, Q3 2026 earnings call, October 29, 2026

> "telemedicine without a physical link is an imperfect offering" — Mark S. Ordan, Chief Executive Officer, Q2 2026 earnings call, August 4, 2026

> "our adjusted EBITDA will be fairly ratable in the third and fourth quarters." — Kasandra H. Rossi, Chief Financial Officer, Q2 2026 earnings call, August 4, 2026


## Where a supplier can help

- **Telehealth platform and devices**: The nationwide telehybrid build-out across MFM, neonatology, retinopathy, neurology and infectious disease needs virtual-care software, remote imaging and connectivity suppliers.
- **Revenue cycle automation**: With the hybrid revenue cycle model now steady and further automation being explored, billing, coding and collections technology can protect pricing as the collections tailwind fades.
- **Physician recruiting and retention**: Clinical salary growth and physician recruitment and retention risk make staffing, credentialing and workforce-scheduling tools relevant to the OB hospitalist and telehybrid expansion.
- **M&A integration support**: The stated appetite for larger women's and children's acquisitions creates demand for diligence, practice integration and IT migration services.
- **Security and AI governance**: Cybersecurity, privacy and AI use are named risks while AI documentation tools roll out, a fit for compliance and security vendors.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/893949/000119312526058074/md-20251231.htm)

Annual report · 2026-02-19

- Pediatrix Medical Group (NYSE: MD), Sunrise, Florida, is a US provider of physician services in newborn, maternal-fetal and other pediatric subspecialty care, with approximately 2,295 affiliated physicians practising in 37 states at December 31, 2025, retained by approximately 400 hospitals.
- Neonatology is the core: 1,350 neonatal physicians staff and manage over 360 NICUs in 32 states; over 475 maternal-fetal and obstetric physicians, over 230 pediatric intensivists, 220 pediatric hospitalists and 20 pediatric surgeons complete the network.
- FY2025 net revenue was $1.91 billion, down 4.9% from $2.01 billion after the 2024 exit of almost all office-based practices (other than maternal-fetal medicine) and of primary and urgent care; same-unit net revenue rose 6.2%, driven mainly by reimbursement factors (5.7%): improved collections, higher acuity, payor mix, hospital administrative fees.
- Profitability recovered: net income of $165.4 million versus a $99.1 million net loss in 2024 (which carried a $150.6 million goodwill impairment); Adjusted EBITDA $275.6 million versus $224.0 million; operating margin 10.9%; Adjusted EPS $2.04.
- Revenue mix: net patient service revenue $1,630,517 thousand, hospital contract administrative fees $271,125 thousand (administrative fees about 14% of net revenue), other $12,207 thousand. Payor mix: 70% contracted managed care, 24% government (mainly Medicaid).
- Concentration: the five largest states (Texas, Florida, Georgia, California, Washington) produced about 64% of net revenue; Texas alone about 32%.
- Strategy: build on core competencies and clinical data (BabySteps, a clinical data warehouse on more than 2.1 million patients), technology, same-unit and organic growth through a national sales team, telehealth, and acquisitions in core specialties (one MFM practice plus a multi-practice neonatology/MFM/OB hospitalist deal in 2025).
- Capital: cash $375.2 million, $400.0 million 5.375% notes due 2030, $196.9 million Term A Loan, undrawn $450.0 million revolver (credit agreement matures February 11, 2027); a new $250.0 million buyback authorised August 2025, $83.8 million used in 2025.
- Key risks: Medicaid reform (One Big Beautiful Bill Act), birth-rate decline, state concentration, No Surprises Act and IDR, the hybrid revenue cycle management transition, physician recruitment and retention, malpractice exposure, cybersecurity and AI use.

### [Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/893949/000119312526436952/md-20260930.htm)

Interim report · 2026-10-29

- Q3 2026 net revenue was $501.4 million, up 1.7% from $492.9 million, mainly from recent acquisitions net of dispositions; same-unit revenue rose 0.6% (0.3% reimbursement, 0.3% volume, the volume gain led by maternal-fetal medicine, offset by a decline in newborn nursery).
- Q3 net income fell to $47.0 million from $71.7 million (Q3 2025 had a $20.9 million gain on divested businesses); Adjusted EBITDA $85.5 million versus $87.3 million; Adjusted EPS $0.72 versus $0.67.
- Operating margin slipped to 13.0% from 13.8% as clinical salaries rose faster than revenue; practice salaries and benefits +2.8% to $341.5 million.
- Nine months: net revenue $1.47 billion (+3.2%), same-unit +2.0% (reimbursement +2.9%, volume -0.9% with declines across all service lines), Adjusted EBITDA $220.1 million versus $209.7 million, Adjusted EPS $1.78 versus $1.54.
- Payor mix improved: contracted managed care 72% of net patient service revenue in Q3, government 22% (23% a year earlier).
- One maternal-fetal medicine practice acquired in 2026 for $7.9 million total consideration.
- Heavy buybacks: $147.2 million of stock repurchased in nine months; $228.5 million of the August 2025 $250.0 million programme used by September 30, 2026; diluted share count down to 79.7 million in Q3 from 85.6 million.
- Cash $311.9 million; $400.0 million notes due 2030 and a $178.1 million Term A Loan, now current because the credit agreement matures in February 2027; DSO 42.5 days.
- Policy watch: CMS finalized revisions to the No Surprises Act IDR process in May 2026 (effective August 2026); the proposed 2027 Medicare Physician Fee Schedule cuts the conversion factor by 1.19%; insurers proposed a median ACA premium increase of approximately 15% for 2027.

### [Q3 2026 earnings call transcript](https://www.tradingkey.com/news/transcripts/262255870-tradingkey)

Executive talk · Mark S. Ordan, Chief Executive Officer · 2026-10-29

- Q3 2026 Adjusted EBITDA of $85 million beat expectations "in spite of increasing costs in virtually all areas of providing great health care"; full-year 2026 outlook narrowed to $290 million to $300 million.
- Same-unit revenue was positive with equal contributions from volume and pricing, while pricing began lapping the collections tailwind (an impact of a little over 100 basis points per the CFO).
- Pricing drivers per CFO Kasandra Rossi: payer mix (about 40% of the positive impact), hospital administrative fees (about 25%), acuity (about 15%); payer mix improved by over 70 basis points year over year.
- Buyback: just over 3 million shares bought in Q3; 10 million since August 2025 at an average $23, leaving about 78 million shares outstanding.
- No visible hit from the lapse of ACA subsidies: "we have still seen no clear negative effect to date."
- Out of network is typically less than 5% of the business, so Ordan does not expect the IDR rule changes to be a headwind.
- Growth: telehealth expansion, select OB hospitalist opportunities ahead of 2027 coding changes, and larger acquisitions "in the women's and children's space" funded by a low-leverage balance sheet (leverage just under 1x, cash $312 million).
- Clinical salary growth held at about 3% to 3.5%; hospital subsidies cover "considerably less than half" of NICU practices; no 2027 outlook given.

### [Q2 2026 earnings call transcript](https://www.webull.com/news/15344832414360576)

Executive talk · Mark S. Ordan, Chief Executive Officer · 2026-08-04

- Q2 2026 Adjusted EBITDA of $76 million, in line with expectations; full-year 2026 outlook of $280 million to $300 million reaffirmed, with H2 Adjusted EBITDA expected "fairly ratable" between Q3 and Q4.
- Consolidated revenue +4%; same-unit +2%, with same-unit pricing +4% (RCM collections, payer mix, acuity) and volumes -2%; NICU days down 3%.
- Payer mix improved 135 basis points year over year and 120 basis points versus Q1; no sign yet of ACA subsidy lapse effects, which Ordan links to the higher value of insurance for pregnant women.
- Strategy: building a nationwide telehybrid offering on top of its physical footprint (over 170 MFMs, over 360 NICUs in 32 states), extending into retinopathy, neurology, infectious disease and neonatology; expanding OB hospitalist services across 400+ hospital relationships; leaders recruited for both.
- Capital: "we're not a bank"; looking at growth within women's and children's medicine, including with outside JV and capital investors; buybacks continue (7 million shares since August 2025, 81 million outstanding).
- Cash $289 million, total debt $584 million, leverage just above 1x; 2026 G&A guided to $230-240 million, at the higher end due to executive transition costs.
- Volumes for the year expected flat to slightly down; salary increases held at 3% to 3.5%.

## Questions about Pediatrix Medical Group

### What does Pediatrix Medical Group do?

Pediatrix provides physician services in newborn, maternal-fetal and other pediatric subspecialty care. Its affiliated physicians staff and manage over 360 NICUs in 32 states and are retained by approximately 400 hospitals.

### What is Pediatrix's revenue?

FY2025 net revenue was $1.91 billion, with net income of $165.4 million and Adjusted EBITDA of $275.6 million. Nine-month 2026 net revenue was $1.47 billion.

### How many physicians work with Pediatrix?

At December 31, 2025 the network had approximately 2,295 affiliated physicians in 37 states, plus approximately 2,020 other clinical professionals.

### What is Pediatrix's strategy?

It is refocused on hospital-based and maternal-fetal medicine care, building nationwide telehybrid services, expanding OB hospitalist services, and looking for acquisitions in women's and children's health.

### Who leads Pediatrix Medical Group?

Mark S. Ordan is Chief Executive Officer and Kasandra H. Rossi is Chief Financial Officer.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
